MedTrace Logo

Pregabalin Versus Placebo In The Treatment Of Neuropathic Pain Associated With HIV Neuropathy

NCT01049217 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 377

Last updated 2021-01-28

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the efficacy of pregabalin compared to placebo in reducing neuropathic pain associated with HIV neuropathy.

Conditions

Interventions

DRUG

pregabalin

Pregabalin 75 mg-300mg twice daily during the course of the study.

DRUG

placebo

Subjects may be assigned to placebo during this study. The study duration is approximately 19 weeks.

Sponsors & Collaborators

  • Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

    lead INDUSTRY

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-04-30
Primary Completion
2012-05-31
Completion
2012-05-31

Countries

  • United States
  • Colombia
  • Dominican Republic
  • India
  • Peru
  • Poland
  • Puerto Rico
  • South Africa
  • Thailand

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01049217 on ClinicalTrials.gov